The DLQI was introduced in 1994 and has since been used to determine the magnitude of effect that skin disease has on a patient’s life [1,2]. Items 3–10 of the DLQI questionnaire include an NRR option. These questions comprise the influence of shopping, social/leisure activities, sex, sports, and work/studying. In some countries, reaching a certain DLQI score is a prerequisite for health insurance to render a patient with psoriasis eligible for systemic treatment [1].
“Most European countries, Ireland included, went through a series of lockdowns and we hypothesised that because people were not able to access shops, gyms, and restaurants, more ‘non-relevant’ responses would be ticked on DLQI questionnaires,” Dr Ali Alsharqi (St. Vincent’s University Hospital, Ireland) explained the study’s aim [1]. Previous research had found that 38.8% of psoriasis patients generally choose an NRR at least once in their questionnaires. It was suggested that more than 1 NNR would decrease the DLQI score, and a formula was created that led to a score adjustment for NRR: the DLQI-R [3]. A second interest of the single centre, retrospective study was to evaluate potential differences in DLQI and DLQI-R during the lockdown phases of the pandemic [1].
The 52 participants all had stable disease, reflected by a Psoriasis Area Severity Index (PASI) score of ≤4. The mean age of the study subjects was 55.3 years, and 53.8% were women. Unsurprisingly in the setting of a specialist clinic, the vast majority was treated with biologics or other systemic drugs. Assessed were the most current DLQI scores obtained before lockdown restrictions and during the lockdown. The results showed similar mean disease activity before (PASI 2.16) and during lockdown (PASI 2.09). Looking at the DLQI in general, the mean scores slightly dropped with 3.13 pre-pandemic and 3.0 during the restrictions. However, mean values for NRRs increased during the lockdown (0.62 vs 1.27), and the picture changed when adjusted for these NRRs with the DLQI-R. “There was a statistically significant increase in the number of NNRs and that corresponded to a statistically significant increase in the DLQI-R,” Dr Alsharqi highlighted, pointing out that the numerical scores for interpersonal relationships, social/leisure, shopping/garden, and home were higher during lockdowns than in pre-pandemic research.
“We think it is important for clinicians to be aware of this, as they make decisions with respect to continuation or altering patient’s treatments and also when it comes to data collection in registries,” Dr Alsharqi summarised the findings.
- Alsharqi A. Are we underestimating Dermatology Life Quality Index Values in the Era of COVID-19? FC12, Psoriasis Gene to Clinic 2021, 9–11. December.
- Finlay AY, et al. Clin Exp Dermatol. 1994;19(3):210–216.
- Rencz F, et al. J Eur Acad Dermatol Venereol. 2018;32(5):783–790.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Inclisiran Lowers Cholesterol Across All BMI groups Next Article
Explaining arthropathy development through IL-4 and IL-13 blockade »
« Inclisiran Lowers Cholesterol Across All BMI groups Next Article
Explaining arthropathy development through IL-4 and IL-13 blockade »
Table of Contents: PFGC 2021
Featured articles
Letter from the Editor
Guselkumab shows highest drug survival among systemic treatments
Genes in Psoriasis and Psoriatic Arthritis
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario
Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis
Comorbidity in Psoriasis
Psoriasis associated with a higher cancer risk
Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status
Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation
Psoriasis Therapy: New Findings
Inhibition of heat shock protein: A novel way to treat psoriasis?
Guselkumab shows highest drug survival among systemic treatments
Tapering biologics: No alarming signs of increased anti-drug antibodies
Intermediate monocytes are possible predictors of response to secukinumab
Gut microbiota of psoriasis patients: less diverse and reduced functionality
COVID-19: What's New
DLQI scores underestimated during lockdowns?
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
Paradoxical Reactions to Biologics
The Yin and Yang of opposing vectors: an explanation for side effects of biologics
Explaining arthropathy development through IL-4 and IL-13 blockade
Best of the Posters
Potential biomarker discovered for treatment response to ustekinumab
TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis
Secukinumab also tolerable in paediatric psoriasis patients
High treatment success with ixekizumab in patients with psoriasis and diabetes
Related Articles
September 17, 2021
Potential role of inflammation in cardiovascular comorbidity
May 31, 2024
What’s new in clinical dermatology?
June 21, 2019
Small molecules, apremilast, and TYK2
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com